Semaglutide Ameliorates Neuroinflammation Caused by Enterogenous Pyrogen in APP/PS1 Mice

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background and purpose: Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive dysfunction, which is common in the elderly. In recent years, it has been reported that glucagon-like peptide 1 (GLP-1) analogues have neuroprotective function. However, the mechanism of GLP-1 analogues improving neurological function has not been fully clarified. This study attempts to clarify the mechanism of GLP-1 alleviating AD phenotype. Methods: In this study, a modified once-weekly GLP-1 analogue, Semaglutide, was used to treat 8-month-old amyloid precursor protein / presenilin 1 (APP/PS1) transgenic mice. By means of ethology, molecular biology and 16s rRNA amplicon sequencing, it was confirmed that Semaglutide alleviated the disease phenotype of APP/PS1 mice. Results: GLP-1 improved the behavioral performance of APP/PS1 mice, reduced neuronal damage and aggregation of amyloid-β (Aβ) plaques, and enhanced synaptic plasticity. GLP-1 also attenuated pyroptosis mediated by NOD-like receptor thermal protein domain associated protein 3 (NLRP3), inflammatory reaction mediated by toll-like receptor 4 (TLR4) and mitochondrial damage of microglia as well as improved the structure and function of blood-brain barrier (BBB) in AD mice. Conclusion: GLP-1 may repair the blood-brain barrier to alleviate the central nervous system injury caused by the displacement of pyrogen in gut of AD mice.

Article activity feed